These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 35137343

  • 1. Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms.
    Matsumoto K, Ohara T, Fujisawa M, Takaki A, Takahara M, Kato H, Yoshida R, Umeda Y, Yagi T, Matsukawa A, Okada H.
    J Gastrointest Surg; 2022 Jun; 26(6):1213-1223. PubMed ID: 35137343
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
    Sakata KK, Midthun DE, Mullon JJ, Kern RM, Nelson DR, Edell ES, Schiavo DN, Jett JR, Aubry MC.
    Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
    [Abstract] [Full Text] [Related]

  • 3. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, Staerkel G, Roy-Chowdhuri S.
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [Abstract] [Full Text] [Related]

  • 4. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A.
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [Abstract] [Full Text] [Related]

  • 5. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M, Patrucco F, Gavelli F, Airoldi C, Sciortino G, Chiaramonte C, Rena O, Balbo PE, Boldorini RL.
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [Abstract] [Full Text] [Related]

  • 6. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
    Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P.
    Ann Oncol; 2016 Jan; 27(1):147-53. PubMed ID: 26483045
    [Abstract] [Full Text] [Related]

  • 7. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R, Giovacchini CX, Liu B, Green CL, Clarke JM, Mahmood K, Pavlisko EN.
    J Am Soc Cytopathol; 2020 Jan; 9(6):485-493. PubMed ID: 32336671
    [Abstract] [Full Text] [Related]

  • 8. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
    Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y.
    Clin Lung Cancer; 2015 Sep; 16(5):385-90. PubMed ID: 25937270
    [Abstract] [Full Text] [Related]

  • 9. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.
    Gompelmann D, Sinn K, Brugger J, Bernitzky D, Mosleh B, Prosch H, Geleff S, Blessing A, Tiefenbacher A, Hoetzenecker K, Idzko M, Hoda MA.
    J Cancer Res Clin Oncol; 2023 May; 149(5):1747-1754. PubMed ID: 35708777
    [Abstract] [Full Text] [Related]

  • 10. The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer.
    Matsumoto K, Ohara T, Fujisawa M, Takaki A, Takahara M, Tanaka N, Kato H, Horiguchi S, Yoshida R, Umeda Y, Fushimi S, Yagi T, Matsukawa A, Okada H.
    J Gastroenterol; 2019 Nov; 54(11):1019-1028. PubMed ID: 31032528
    [Abstract] [Full Text] [Related]

  • 11. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Yoshimura K, Inoue Y, Karayama M, Tsuchiya K, Mori K, Suzuki Y, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Yokomura K, Inui N, Funai K, Shinmura K, Niwa H, Suda T, Sugimura H.
    Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
    [Abstract] [Full Text] [Related]

  • 12. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A, Siegel L, Freese R, Racila E, Stewart J, Amin K.
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [Abstract] [Full Text] [Related]

  • 13. PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.
    Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Hoque MO, Moretta F, Mingari MC, Pegoraro MC, Inno A, Paiano S, Terzi A, Cavazza A, Rossi G, Mariotti FR, Vacca P, Moretta L, Bogina G.
    J Thorac Oncol; 2018 Aug; 13(8):1113-1120. PubMed ID: 29704674
    [Abstract] [Full Text] [Related]

  • 14. Correlation of programmed death-ligand 1 expression in tumour cells between diagnostic small biopsies performed by radial EBUS and surgical specimens of peripheral lung cancer.
    Lachkar S, Gervereau D, Loïc P, De Marchi M, Morisse H, Dantoing E, Piton N, Thiberville L, Salaün M, Guisier F.
    BMJ Open Respir Res; 2024 Oct 15; 11(1):. PubMed ID: 39414327
    [Abstract] [Full Text] [Related]

  • 15. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD, Abengozar-Muela M, Echeveste JI, Subtil JC, Bertó J, Gúrpide A, Calvo A, de Andrea CE.
    Cancer Cytopathol; 2019 Jul 15; 127(7):470-480. PubMed ID: 31245924
    [Abstract] [Full Text] [Related]

  • 16. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr 15; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 17. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A, Morikawa K, Inoue T, Miyazawa T, Hoshikawa M, Takagi M, Mineshita M.
    BMC Cancer; 2019 Jun 07; 19(1):546. PubMed ID: 31174496
    [Abstract] [Full Text] [Related]

  • 18. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
    Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G.
    J Thorac Oncol; 2017 Oct 07; 12(10):1536-1543. PubMed ID: 28751245
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z, Williams M, Stewart J, Glisson BS, Fuller C, Roy-Chowdhuri S.
    Cancer Cytopathol; 2022 Feb 07; 130(2):110-119. PubMed ID: 34375025
    [Abstract] [Full Text] [Related]

  • 20. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
    Mei P, Shilo K, Wei L, Shen R, Tonkovich D, Li Z.
    Cancer Cytopathol; 2019 Jul 07; 127(7):447-457. PubMed ID: 31025831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.